Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Sponsor: VivaVision Biotech, Inc
Summary
This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China
Official title: A Multi-center, Randomized, Single-masked, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 1.0% VVN461 Ophthalmic Solution in Patients With Non-infectious Anterior Uveitis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
154
Start Date
2025-11-25
Completion Date
2027-04-30
Last Updated
2026-08-24
Healthy Volunteers
No
Conditions
Interventions
VVN461 Ophthalmic Solution 1.0%
1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
1.0% prednisolone acetate
1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
Locations (2)
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Peking University First Hospital
Beijing, China